PATHOGENETIC HETEROGENITY OF MULTIPLE SCLEROSIS: KEY FOR UNDERSTANDING OF THE DISEASE CLINICAL POLYMORPHISM AND INDIVIDUALIZED THERAPY DEVELOPING



Cite item

Full Text

Abstract

Modern data on pathogenic mechanisms of multiple sclerosis and their correlation with clinical manifestations, course and prognosis of the disease, as well as possibilities and limitations of contemporary pathogenic therapy were presented. There was considered a variety of immunomodelling preparations, influencing the basic pathogenetic mechanisms of multiple sclerosis, as well as necessity of creating markers, reflecting a pathogenetic mechanism in a certain patient for the aim of substantial therapeutic effectiveness.

About the authors

Timur Ildusovich Khaibullin

1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

Email: timuur@gmail.com
1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

Farit Аhatovich Khabirov

1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

Farida Ildusovna Devlikamova

1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

1) Каzan State Medical Academy of Russian Health Ministry,2) Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

Natalya Nikolaevna Babicheva

Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

Republican Clinical-and-Diagnostic Centre for demyelinization diseases of Health Ministry of the Republic of Tatarstan

References

  1. Бойко, А.Н. Патогенетическое лечение рассеянного склероза: настоящее и будущее / А.Н. Бойко, И.Д. Столяров, Т.В. Сидоренко и др. // Журн. неврол. и психиатр. им. С.С. Корсакова. - 2009. - Спец. выпуск «Рассеянный скле- роз» 2. - Т. 109. - С. 90-100.
  2. Гусев, Е.И. Рассеянный склероз и другие демиелинизирующие заболевания / Е.И. Гусев, И.А. Завали-шин, А.Н. Бойко. - М.: Миклош, 2004. - 540 с.
  3. Давыдовская, М.В. Нейродегенеративный процесс при рассеянном склерозе и возможные пути его коррекции / М.В. Да-выдовская, А.Н. Бойко, Е.И. Гусев // Журн. неврол. и психиатр. им. С.С. Корсакова. - 2009. - Спец. выпуск «Рассеянный склероз» 2. - Т. 109. - С 44-53.
  4. Захарченко, М.А. Курс нервных болезней / М.А. За-харченко. - Москва-Ленинград: Государственное издательство, 1930. - 932 с.
  5. Клинические рекомендации. Неврология и нейрохирургия [под ред. Е.И. Гусева, А.Н. Коновалова, А.Б. Гехт]. - М.: ГЭОТАР-Медиа, 2008. - 368 с.
  6. Ройт, А. Иммунология. Пер. с англ. / А. Ройт, Дж. Бростофф, Д. Мейл. - М: Мир, 2000. - 592 с.
  7. Сидоренко, Т.В. Натализумаб: новый препарат для лечения рассеянного склероза. / Т.В. Сидоренко, Е.В. Кольяк, А.Н. Бойко. // Журн. неврол. и психиатр. им. С.С. Корсакова. - 2009. - Спец. выпуск «Рассеянный склероз» 2. - Т. 109. - С.122-129.
  8. Хондкариан, О.А. Рассеянный склероз / О.А. Хонд-кариан, И.А. Завалишин, О.М. Невская. - М.: Медицина, 1987. - 256 с.
  9. Association for research in nervous & mental diseases: Volume 2: Multiple sclerosis. - New York, 1921. - 240 p.
  10. Bitsch, A. Differentiation of multiple sclerosis subtypes: implications for treatment / A. Bitsch, W. Bruck // CNS Drugs. - 2002. - Vol. 16 (6). - P. 405-418.
  11. Bruck, W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis / W. Bruck // J. Neurol. - 2005. - Vol. 252 (5). - P. 10-15.
  12. Cantorna, M.T. Vitamin D and multiple sclerosis: an update / M.T. Cantorna // Nutrition Reviews. - Vol. 66 (2). - P. 135-138.
  13. Carson, M.J. CNS immune privilege: hiding in plain sight / M.J. Carson, J.M. Doose, B. Melchior [et al.] // Immunological Reviews. - 2006. - Vol. 213. - P. 48-65.
  14. Correale, J. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting / J. Correale, A.S. Villa // Autoimmunity. - 2007. - Vol. 40. - P. 148-160.
  15. Cruse, J.M. Illustrated dictionary of immunology / J.M. Cruse, R.E. Lewis. - CRC Press, 2009. - 762 p.
  16. Czlonkowska, A. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases / A. Czlonkowska, A. Ciesielska, G. Gromadzka et al. // Current Pharmaceutical Design. - 2005. - Vol. 11. - P. 1017-1030.
  17. Delgado, S. The role of CD4+ T-cells in the development of MS / S. Delgado, W.A. Sheremata // Neurological Research. - 2006. - Vol. 28. - P. 245-249.
  18. Franklin, R.J. Remyelination in the CNS: from biology to therapy / R.J. Franklin, C. Ffrench-Constant // Nature neuroscience. - 2008. - Vol. 9. - P. 830-855.
  19. Genain, C.P. Identification of autoantibodies associated with myelin damage in multiple sclerosis / C.P. Genain, B. Can-nella, S.L. Hauser et al. // Nature Medicine. - 1999. - Vol. 5. - P. 170-175.
  20. Gilgun-Sherki, Y. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy / Y. Gilgun-Sherki, E. Melamed, D. Offen // J. Neurol. - 2004. - Vol. 251. - P. 261-268.
  21. Gironi, M. Immunological markers in multiple sclerosis / M. Gironi, A. Bergami, E. Brambilla [et al.] // Neurol. Sci. - 2000. - Vol. 21. - P. 871-875.
  22. Hafler, D.A. Multiple sclerosis / D.A. Hafler // J. Clin. Invest. - 2004. - Vol. 113. - P. 788-794.
  23. Hafler, D.A. Multiple sclerosis / D.A. Hafler, J.M. Slavik, D.E. Anderson et al. // Immunological Reviews. - 2005. - Vol. 204. - P. 208-231.
  24. Hafler, D.A. Immunologic mechanisms and therapy in multiple sclerosis / D.A. Hafler, H.L. Weiner / Immun. Rev. - 1995. - Vol. 144. - P. 75-107.
  25. Hemmer, B. New concepts in the immunopathogenesis of multiple sclerosis / B. Hemmer, J.J. Archelos, H.P. Hartung // Nature neuroscience. - 2002. - Vol. 3. - P. 291-301.
  26. Hohlfeld, R. 'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009 / Hohlfeld R. // Multiple Sclerosis. - 2010. - Vol. 16 (1). - P. 3-14.
  27. Kanda, T. Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model / T. Kanda, T. Iwasaki, M. Ya-mawaki et al. // Neurology. - 2000. - Vol. 55. - P. 585-587.
  28. Korn, T. Pathophysiology of multiple sclerosis / T. Korn // J. Neurol. - 2008. - Vol. 255 (6). - P. 2-6.
  29. Lalazar, G. Glycolipids as immune modulatory tools / G. La-lazar, S. Preston, E. Zigmond et al. // Mini Rev. Med. Chem. - 2006. - Vol. 6. - P. 1249-1253.
  30. Lassmann, H. Recent neuropathological findings in MS - implications for diagnosis and therapy / H. Lassman // J. Neurol. - 2004. - Vol. 251 (4). - P. 2-5.
  31. Lily, O. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study / O. Lily, J. Palace, A. Vincent // Brain. - 2004. - Vol. 127. - P. 269-279.
  32. Lucchinetti, C. The pathology of primary progressive multiple sclerosis / C. Lucchinetti, W. Bruck // Multiple Sclerosis. - 2004. - Vol. 10. - P. 23-30.
  33. Lucchinetti, C. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination / C. Lucchinetti, W. Bruck, J. Parisi et al. // Ann. Neurol. - 2000. - Vol. 47. - P. 707-717.
  34. Maggs, F.G. The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? / F.G. Maggs, J. Palace // Multiple Sclerosis. - 2004. - Vol. 10. - P. 326-329.
  35. Martin, R. HLA class I: friend and foe of multiple sclerosis / R. Martin // Nature Medicine. - 2008. - Vol. 14. - P. 1150-1151.
  36. McDole, J. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis / J. McDole, A.J. Johnson, I. Pirko // Neurological Research. - 2006. - Vol. 28. - P. 256-261.
  37. McFarland, H.F. Multiple sclerosis: a complicated picture of autoimmunity / H.F. McFarland, R. Martin // Nature immunology. - 2007. - Vol. 8. - P. 913-919.
  38. Menge, T. Disease-modifying agents for multiple sclerosis: recent advances and future prospects / T. Menge, M.S. Weber, B. Hemmer et al. // Drugs. - 2008. - Vol. 68. - P. 2445-2468.
  39. Merrill, J.E. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease / J.E. Merrill, N.J. Scolding // Neuropathology and Applied Neurobiology. -1999. - Vol. 25. - P. 435-458.
  40. Neumann, H. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases / H. Neumann // Curr. Opin. Neurol. - 2003. - Vol. 16. - P. 267-273.
  41. Paz Soldan, M.M. Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination / M.M. Paz Soldan, M. Rodriguez // The Journal of Infectious Diseases. - 2002. - Vol. 186 (2). - P. 248-253.
  42. Podbielska, M. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? / M. Podbielska, E.L. Hogan // Multiple Sclerosis. - 2009. - Vol. 15 (9). - P. 1011-1029.
  43. Rodriguez, M. Effectors of demyelination and remyeli-nation in the CNS: implications for multiple sclerosis / M. Rodriguez // Brain Pathol. - 2007. - Vol. 17. - P. 219-229.
  44. Schmidt, S. Candidate autoantigens in multiple sclerosis / S. Schmidt // Multiple Sclerosis. - 1999. - Vol. 5. - P. 147-160.
  45. Sospedra, M. Immunology of multiple sclerosis / M. Sospedra, R. Martin // Annu. Rev. Immunol. - 2005. - Vol. 23. - P. 683-747.
  46. Stangel, M. Neuroprotection and neuroregeneration in multiple sclerosis / M. Stangel // J. Neurol. - 2008. - Vol. 255 (6). - P. 77-81.
  47. Steinman, L. Multiple sclerosis: a two-stage disease / L. Stein-man // Nature immunology. - 2001. - Vol. 2. - P. 762-764.
  48. Steinman, L. Nuanced roles of cytokines in three major human brain disorders / L. Steinman // J. Clin. Invest. - 2008. - Vol. 118. - P. 3557-3563.
  49. Svejgaard, A. The immunogenetics of multiple sclerosis // Immunogenetics. - 2008. - Vol. 60. - P. 275-286.
  50. Tesmer, L.A. Th17 cells in human disease / L.A. Tesmer, S.K. Lundy, S. Sarkar et al. // Immunological Reviews. - 2008. - Vol. 223. - P. 87-113.
  51. Vanderlug, C.L. Epitope spreading in immunemediated diseases: implications for immunotherapy / C.L. Vanderlugt, S.D. Miller // Nature reviews: immunology. - 2002. - Vol. 2. - P. 85-95.
  52. Vyshkina, T. Autoantibodies and neurodegeneration in MS / T. Vyshkina, B. Kalman // Lab. Inv. -2008. - Vol. 88. - P. 796-807.
  53. Waxman, S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels / S.G. Waxman // Nature Reviews: neuroscience. - 2006. - Vol. 7. - P. 932-941.
  54. Zaffaroni, M. Biological indicators of the neurodegenerative phase of multiple sclerosis / M. Zaffaroni // Neurol. Sci. - 2003. - Vol. 24 (5). - P. 279-282.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Khaibullin T.I., Khabirov F.А., Devlikamova F.I., Babicheva N.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies